Table 5.

The effect of the frequency of deworming on absolute scaled development scores at 24 months, using unadjusted and adjusted ANOVA analysis, n=1320^a, Iquitos, Loreto, Peru (September 2011–July 2013).

	MBD/PBOb1	PBO/MBDb2	MBD/MBDb3
	(n=440)	(n=440)	(n=440)
Cognition
Unadjusted difference	−0.17	0.04	Reference
(95% CI)	(−0.34, 0.01)	(−0.13, 0.22)
p Value	0.063	0.630
Adjustedc difference	−0.12	0.06	Reference
(95% CI)	(−0.29, 0.05)	(−0.12, 0.23)
p Value	0.168	0.529
Receptive language
Unadjusted difference	0.03	0.08	Reference
(95% CI)	(−0.14, 0.20)	(−0.09, 0.26)
p value	0.713	0.343
Adjusted difference	0.06	0.09	Reference
(95% CI)	(−0.11, 0.23)	(−0.08, 0.26)
p Value	0.480	0.305
Expressive language
Unadjusted difference	0.05	0.06	reference
(95% CI)	(−0.16, 0.25)	(−0.15, 0.27)
p value	0.657	0.587
Adjusted difference	0.08	0.04	Reference
(95% CI)	(−0.11, 0.27)	(−0.17, 0.24)
p value	0.425	0.730
Fine motor skills
Unadjusted difference	0.03	0.16	Reference
(95% CI)	(−0.20, 0.25)	(−0.07, 0.38)
p value	0.827	0.173
Adjusted difference	0.06	0.16	reference
(95% CI)	(−0.17, 0.28)	(−0.07, 0.38)
p Value	0.624	0.169

Results are expressed as mean (95% confidence interval).

^aIntention-to-treat analysis includes data from 1167 children for whom final outcome information was available, and 153 children who were lost to follow-up and whose outcome information was estimated using multiple imputation.

^b1Group 1 (MBD/PBO)=mebendazole at the 12-month visit and placebo at the 18-month visit; ²Group 2 (PBO/MBD)=placebo at the 12-month visit and mebendazole at the 18-month visit; ³Group 3 (MBD/MBD)=mebendazole at the 12 and 18-month visit.

^cAdjusted models include age, sex, socioeconomic status, continued breastfeeding at 12 months of age, baseline height and weight, and baseline development score.